



RECEIVED
CENTRAL FAX CENTER

MAR 04 2005

Attorneys at Law
919 N. Market Street
P.O. Box 111
Wilmington, DE 19801-3023
Phone 302.984.6300
Fax 302.984.6399
www.mccarter.com

TAX FILING
U.S. PATENT AND TRADEMARK OFFICE

Total Number of Pages: 6 (Including this Cover Page)

TO: Examlner Stacy Brown Chen	FAX NO: (703) 872-9306
FROM: Basil S. Krikellis	REGISTRATION NO.: 41,129
TELEPHONE NO.: (302) 984-6393	FAX NO.: (302) 984-6399
FIRST INVENTOR: Orn Adalsteinsson, et al.	EXAMINER: Stacy Brown Chen
TITLE OF APPL: GLUCOSAMINE AND EGG FOR REDUCING INFLAMMATION	
SERIAL NO: 10/774,021	FILING DATE: February 6, 2004
ART UNIT: 1648	CONFIRMATION NO. 7718
LIST OF ATTACHMENTS: CERTIFICATE OF FAX TRANSMISSION – 1 PAGE; TRANSMITTAL FORM – 1 PAGE; RESPONSE TO RESTRICTION REQUIRMENT – 2 PAGES; CHANGE OF CORRESPONDENCE ADDRESS – 1 PAGE	
Comments:	
<p>The information contained in the facsimile message is attorneys' privileged and confidential information intended only for the person or entity named above. If you are not the intended recipient (or someone responsible to deliver to the intended recipient), please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us by telephone immediately at (302) 984-6300 and return the original message to us at the above address via the U. S. Postal Service. Thank you.</p>	

MAR 04 2005

PTO/S9/97 (09-09)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (703) 872-9306.

on March 4, 2005
Date

Renée L. Sipple
Signature

RENEE L. Sipple
Typed or printed name of person signing Certificate

Registration Number, if applicable

(302) 984-6393
Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-0199 and select option 2.

PTO/SF/21 (02-04)

Approved for use through 07/31/2005, OMB 0531-0001

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


4

Application Number	10/774,021
Filing Date	February 6, 2004
First Named Inventor	Orn Adalsteinsson, et al.
Art Unit	1648
Examiner Name	Stacy Brown Chen
Attorney Docket Number	CV0070A

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): Change of Correspondence Address
Remarks _____		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	McCarter & English, LLP		
Signature			
Printed name	Basil S. Krikalis		
Date	March 4, 2005	Reg. No.	41,129

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature



Typed or printed name

Renee L. Sipple

Date

March 4, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

MAR 04 2005


CV0070A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No: 10/774,021
Applicant: Orn Adalsteinsson, et al.
Filed: February 6, 2004
Title: GLUCOSAMINE AND EGG FOR REDUCING INFLAMMATION
TC/A.U.: 1648
Examiner: Stacy Brown Chen
Confirmation No.: 7718
Docket No.: CV0070A

CERTIFICATE OF TRANSMITTAL/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO (703-872-9306) or deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: March 4, 2005.


Renee L. Sipple

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed February 7, 2005, our response to the restriction requirement is as follows:

The Examiner has restricted the claims of the application into three groups as follows: Group I (Claims 46 - 51), drawn to a composition comprising glucosamine and an active egg fraction; Group II (Claims 52 - 55), drawn to a method for reducing serum fibrinogen levels; and Group III (Claims 56 - 59) drawn to a method of reducing or preventing the onset of rheumatoid arthritis.


Applicant elects Group I (Claims 46 - 51) with traverse as to the restriction between Group I and Groups II and III. Specifically, Applicant submits that a thorough search for Group I should also include the subject matter of Group II and III, since a desirable use for a

CV0070A

composition comprising glucosamine and an egg product would be to reduce serum fibrinogen levels and rheumatoid arthritis. In the present case, the subject matter of these Groups cited by the Examiner is sufficiently small and is so closely related as to be capable of examination together. In any event, if the elected claims of Group I are found allowable, Applicant reserves its right to amend the method claims of Groups II and III to be commensurate in scope with the product claims of Group I, and to request that such amended claims that depend from or otherwise include all the limitations of the allowable product be rejoined and examined for patentability. In re Brower, 37 USPQ2d 1663 (Fed. Cir. 1996) ; In re Ochiai, 37 USPQ2d 1127 (Fed. Cir. 1995); MPEP § 821.04.

In view of the foregoing remarks, Applicant respectfully requests that the Examiner withdraws the requirement for an election between Groups I, II and III.

Respectfully submitted,



Basil S. Krikélis
Registration No. 41,129
Attorney for Applicant(s)

Dated: March 4, 2004

BSK/rls

McCarter & English, LLP
Citizens Bank Center
919 N. Market Street
Suite 1800
P.O. Box 111
Wilmington, DE 19899